6505--Bupropion Tablets 12hr SA Tablets
ID: 36E79725R0065Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/0568b659e77947fd84153cf8195543de/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the supply of Bupropion Hydrochloride (HCL) 12-hour Sustained Action (SA) Tablets through solicitation number 36E79725R0065. This procurement aims to establish a reliable supply source for various VA, DoD, IHS, and BOP facilities, encompassing five line items with different strengths and package sizes, including 60 and 500 tablets, over a base year and four one-year option periods. The contract emphasizes compliance with federal regulations, including the Drug Supply Chain Security Act, and requires offerors to submit pricing for all line items, provide a unique 11-digit National Drug Code (NDC) for each product, and include a 0.5% Cost Recovery Fee in their pricing. Interested parties should contact Contract Specialist Deborah S. Fassl at Deborah.Fassl@va.gov for further details and clarification.

    Point(s) of Contact
    Deborah S FasslContract Specialist
    Deborah.Fassl@va.gov
    Files
    Title
    Posted
    36E79725R0065_1.docx
    The VA National Acquisition Center plans to issue RFP #36E79725R0065 for an unrestricted procurement of Bupropion Hydrochloride (HCL) 12-hour Sustained Action (SA) Tablets. This contract will supply the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The awarded contract will be for one year with four one-year option periods, requiring an uninterrupted source of supply. Offerors must provide products with unique NDC numbers and specific packaging requirements, including safety-caps and bottle dimensions. The solicitation, expected around November 4, 2025, with a tentative closing date of November 18, 2025, will be issued electronically via SAM.gov. The NAICS code is 325412. Estimated annual requirements are provided for 100mg, 150mg, and 200mg tablets in various bottle sizes. Deb Fassl is the point of contact for inquiries.
    36E79725R0065.docx
    This government solicitation, 36E79725R0065, from the Department of Veterans Affairs, outlines an RFP for Bupropion Hydrochloride (HCL) 12-hour Sustained Action (SA) Tablets. The contract will establish a supply source for VA, DoD, IHS, and BOP facilities through Pharmaceutical Prime Vendor (PPV) Programs. It includes five line items for varying strengths and package sizes (60 and 500 tablets) with a base year and four one-year option periods. Key requirements for offerors include submitting prices for all line items and option years, providing a unique 11-digit National Drug Code (NDC) for each product, and including a 0.5% Cost Recovery Fee in their pricing. Distributors must provide a Letter of Commitment from the manufacturer. The document details packaging specifications, barcoding requirements (GS1-128 or HIBCC HIBC), and compliance with the Drug Supply Chain Security Act (DSCSA) for serialized transaction information. Manufacturers must maintain an acceptable current Good Manufacturing Practices (cGMP) status with the FDA, and timely notification of any cGMP violations or product recalls is mandatory. The contract emphasizes adherence to federal regulations and outlines terms for contract duration, backorders, and payment through PPV programs.
    Lifecycle
    Title
    Type
    6505--Bupropion Tablets 12hr SA Tablets
    Currently viewing
    Solicitation
    6505--Bupropion Tablets 12hr SA Tablets
    Presolicitation
    Similar Opportunities
    6505--Zonisamide Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the unrestricted procurement of Zonisamide Capsules, which will serve various federal entities including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will be awarded to a single offeror capable of providing an uninterrupted supply of the specified medications, with a contract period of one year and four optional one-year extensions. The procurement is critical for ensuring the availability of these pharmaceutical products, which are essential for patient care within the VA and other federal health facilities. Interested parties should monitor SAM.gov for the solicitation, expected to be issued around December 15, 2025, with a closing date of December 30, 2025, and may direct inquiries to Chris Carthron at Christopher.Carthron@va.gov.
    Sertraline Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for the procurement of Sertraline Tablets in 25MG, 50MG, and 100MG dosages, with various bottle counts required over a base year and four option years. This solicitation, identified as SPE2D2-26-R-0002, emphasizes the importance of these pharmaceuticals in supporting military personnel's health and well-being. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 10, 2025, at 3:00 PM EST, and adhere to specific contractual obligations, including a subcontracting plan and compliance with various FAR and DFARS clauses. For further inquiries, potential bidders can contact Christopher Newman at christopher.newman@dla.mil or Jason Wray at jason.wray@dla.mil.
    Metaxalone Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in both 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal regulations and the submission of a subcontracting plan for large businesses. Metaxalone is a critical medication used for muscle relaxation, highlighting the importance of reliable supply for military personnel. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, at 3:00 PM EST, and can reach out to Jeremy Brown or Jason Wray for further inquiries.
    Ondansetron Orally Disintegrating Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Ibuprofen 400MG/600MG/800MG Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.